Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Short term Debt: 2020-2022

Historic Short term Debt for Arcturus Therapeutics Holdings (ARCT) over the last 2 years, with Dec 2022 value amounting to $60.7 million.

  • Arcturus Therapeutics Holdings' Short term Debt rose 169.89% to $60.7 million in Q4 2022 from the same period last year, while for Dec 2022 it was $60.7 million, marking a year-over-year increase of 169.89%. This contributed to the annual value of $60.7 million for FY2022, which is 169.89% up from last year.
  • According to the latest figures from Q4 2022, Arcturus Therapeutics Holdings' Short term Debt is $60.7 million, which was up 118.96% from $27.7 million recorded in Q3 2022.
  • In the past 5 years, Arcturus Therapeutics Holdings' Short term Debt registered a high of $60.7 million during Q4 2022, and its lowest value of $1.2 million during Q4 2020.
  • Its 3-year average for Short term Debt is $21.1 million, with a median of $22.5 million in 2021.
  • Data for Arcturus Therapeutics Holdings' Short term Debt shows a peak YoY skyrocketed of 1,697.92% (in 2021) over the last 5 years.
  • Arcturus Therapeutics Holdings' Short term Debt (Quarterly) stood at $1.2 million in 2020, then skyrocketed by 1,697.92% to $22.5 million in 2021, then skyrocketed by 169.89% to $60.7 million in 2022.
  • Its Short term Debt was $60.7 million in Q4 2022, compared to $27.7 million in Q3 2022 and $27.0 million in Q2 2022.